Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer

Abstract

Background

Several recent studies have focused on the association between background parenchymal enhancement (BPE) and tumor response to neoadjuvant chemotherapy (NAC), but early prediction of tumor response based on BPE has yet not been investigated.

Purpose

To retrospectively investigate whether changes in the BPE of the contralateral breast following NAC could help predict tumor response in early stage HER2-positive breast cancer.

Material and Methods

Data from 71 patients who were diagnosed with unilateral HER2 positive breast cancer and then underwent NAC with trastuzumab before surgery were analyzed retrospectively. Two experienced radiologists independently categorized the patients’ levels of BPE of the contralateral breast into four categories (1 = minimal, 2 = mild, 3 = moderate, 4 = marked) at baseline and after the second cycle of NAC. After undergoing surgery, 34 patients achieved pathologic complete response (pCR) and 37 patients had residual disease (non-pCR). The association between BPE and histopathologic tumor response was analyzed.

Result

The level of BPE was higher in premenopausal than post-menopausal women both at baseline and after the second cycle of NAC (P < 0.005). A significant reduction in BPE (P < 0.001) was observed after the second NAC cycle; however, a more obvious decrease in BPE was identified in premenopausal relative to post-menopausal women (P = 0.041). No significant association was identified between pCR and baseline BPE (P = 0.287). However, after the second NAC cycle, decreased BPE was significantly associated with pCR (P = 0.003).

Conclusion

For HER2-positive patients, changes in BPE may serve as an additional imaging biomarker of treatment response at an early stage.

Keywords

Background parenchymal enhancement magnetic resonance imaging (MRI)HER2-positive breast cancer neoadjuvant chemotherapy tumor response

Get full access to this article

View all access options for this article.

References

Ikeda

Hylton

Kuhl

et al.

BI-RADS: Magnetic Resonance Imaging. In: D’Orsi

Mendelson

Ikeda

et al. (eds). Breast Imaging Reporting and Data System: ACR BI-RADS, breast imaging atlas, 1st ed. Reston, VA: American College of Radiology, 2003.

Sippo

Warden

Andriole

et al.

Automated extraction of BI-RADS final assessment categories from radiology reports with natural language processing. J Digit Imaging 2013; 26: 989–994.

Morris

Comstock

Lee

et al.

BI-RADS: magnetic resonance imaging 2013. In: D’Orsi

Sickles

Mendelson

et al. (eds). Breast Imaging Reporting and Data System: ACR BI-RADS, breast imaging atlas, Reston, VA: American College of Radiology, 2013, pp. 27–32.

Giess

Yeh

Raza

et al.

Background parenchymal enhancement at breast MR imaging: normal patterns, diagnostic challenges, and potential for false-positive and false-negative interpretation. Radiographics 2014; 34: 234–247.

Kuhl

Bieling

Gieseke

et al.

Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. Radiology 1997; 203: 137–144.

King

Kaplan

et al.

Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI. Eur Radiol 2012; 22: 2641–2647.

Ellis

. Optimal timing of breast MRI examinations for premenopausal women who do not have a normal menstrual cycle. Am J Roentgenol 2009; 193: 1738–1740.

Taylor

Lazberger

Ives

et al.

Reducing delay in the diagnosis of pregnancy-associated breast cancer: how imaging can help us. J Med Imaging Radiat Oncol 2011; 55: 33–42.

King

Kaplan

Pike

et al.

Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging. Breast J 2012; 18: 527–534.

10.

Oksa

Parkkola

Luukkaala

et al.

Breast magnetic resonance imaging findings in women treated with toremifene for premenstrual mastalgia. Acta Radiol 2009; 50: 984–989.

11.

Baek

Kim

Lee

. Background parenchymal enhancement in breast MRIs of breast cancer patients: impact on tumor size estimation. Eur J Radiol 2014; 83: 1356–1362.

12.

Uematsu

Kasami

Watanabe

. Does the degree of background enhancement in breast MRI affect the detection and staging of breast cancer? Eur Radiol 2011; 21: 2261–2267.

13.

Kim

et al.

Enhancement parameters on dynamic contrast enhanced breast MRI: do they correlate with prognostic factors and subtypes of breast cancers?

Magn Reson Imaging 2015; 33: 72–80.

14.

Kim

Cho

Ryu

et al.

Background parenchymal signal enhancement ratio at preoperative MR imaging: association with subsequent local recurrence in patients with ductal carcinoma in situ after breast conservation surgery. Radiology 2014; 270: 699–707.

15.

Choi

et al.

Background parenchymal enhancement on preoperative magnetic resonance imaging: association with recurrence-free survival in breast cancer patients treated with neoadjuvant chemotherapy. Medicine (Baltimore) 2016; 95: e3000–e3000.

16.

van der Velden

Dmitriev

Loo

et al.

Association between parenchymal enhancement of the contralateral breast in dynamic contrast-enhanced MR imaging and outcome of patients with unilateral invasive breast cancer. Radiology 2015; 276: 675–685.

17.

Chen

Hsu

et al.

Background parenchymal enhancement of the contralateral normal breast: association with tumor response in breast cancer patients receiving neoadjuvant chemotherapy. Transl Oncol 2015; 8: 204–209.

18.

Chen

Lin

et al.

Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI. Magn Reson Imaging 2013; 31: 1465–1471.

19.

Preibsch

Wanner

Bahrs

et al.

Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response. Eur Radiol 2016; 26: 1590–1596.

20.

Ogston

Miller

Payne

et al.

A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 2003; 12: 320–327.

21.

Wolff

Hammond

Hicks

et al.

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31: 3997–4013.

22.

Liu

Huang

et al.

Similar prognoses for invasive micropapillary breast carcinoma and pure invasive ductal carcinoma: a retrospectively matched cohort study in China. PLoS One 2014; 9: e106564–e106564.

23.

Cheng

Wang

et al.

18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer. Oncotarget 2015; 6: 29388–29395.

24.

Wang

Morrison

Gillihan

et al.

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers–role of estrogen receptor and HER2 reactivation. Breast Cancer Res 2011; 13: R121–R121.

25.

Vaz-Luis

Winer

Lin

. Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Ann Oncol 2013; 24: 283–291.